Byun, D. J., Wolchok, J. D., Rosenberg, L. M. & Girotra, M. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195–207 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17, 389–399 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corsello, S. M. et al. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361–1375 (2013).

Article  CAS  PubMed  Google Scholar 

Maker, A. V. et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29, 455–463 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torino, F., Barnabei, A., De Vecchis, L., Salvatori, R. & Corsello, S. M. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17, 525–535 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Joshi, M. N., Whitelaw, B. C., Palomar, M. T., Wu, Y. & Carroll, P. V. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin. Endocrinol. 85, 331–339 (2016).

Article  CAS  Google Scholar 

Jessel, S. et al. Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function. Front. Oncol. 12, 836859 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vardarli, I. et al. Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 109, 1132–1144 (2024).

Article  PubMed  Google Scholar 

Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073–4126 (2021).

Article  CAS  PubMed  Google Scholar 

Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217–1238 (2022).

Article  CAS  PubMed  Google Scholar 

Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Arima, H. et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr. J. 66, 581–586 (2019).

Article  CAS  PubMed  Google Scholar 

Iwama, S., Kobayashi, T. & Arima, H. Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors. Endocrinol. Metab. 36, 312–321 (2021).

Article  CAS  Google Scholar 

Kobayashi, T., Iwama, S. & Arima, H. Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events. Endocr. J. 71, 23–29 (2024).

Article  CAS  PubMed  Google Scholar 

Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).

Article  CAS  PubMed  Google Scholar 

Kobayashi, T. et al. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J. Immunother. Cancer 8, e000779 (2020). This prospective study demonstrated that people with non-small-cell lung cancer and malignant melanoma who developed pituitary irAEs had improved survival outcomes compared with those who did not.

Article  PubMed  PubMed Central  Google Scholar 

Caturegli, P. et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225–3235 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanie, K. et al. Two cases of atezolizumab-induced hypophysitis. J. Endocr. Soc. 2, 91–95 (2018).

Article  CAS  PubMed  Google Scholar 

Faje, A. T. et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124, 3706–3714 (2018).

Article  CAS  PubMed  Google Scholar 

Kurokawa, R. et al. MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis. Am. J. Neuroradiol. 41, 1683–1689 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Faje, A. et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur. J. Endocrinol. 181, 211–219 (2019).

Article  CAS  PubMed  Google Scholar 

Caturegli, P. et al. Autoimmune hypophysitis. Endocr. Rev. 26, 599–614 (2005).

Article  CAS  PubMed  Google Scholar 

Inaba, H. et al. Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study. Clin. Endocrinol. 91, 786–792 (2019).

Article  CAS  Google Scholar 

Iglesias, P., Sanchez, J. C. & Diez, J. J. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary 24, 630–643 (2021).

Article  CAS  PubMed  Google Scholar 

Carpenter, K. J., Murtagh, R. D., Lilienfeld, H., Weber, J. & Murtagh, F. R. Ipilimumab-induced hypophysitis: MR imaging findings. Am. J. Neuroradiol. 30, 1751–1753 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, C. et al. Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab. 2, 365–369 (2018).

Article  Google Scholar 

Deligiorgi, M. V., Siasos, G., Vergadis, C. & Trafalis, D. T. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy. Int. Immunopharmacol. 83, 106427 (2020).

Article  CAS  PubMed  Google Scholar 

Yu, M. et al. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report. Immunotherapy 13, 1255–1260 (2021).

Article  CAS  PubMed  Google Scholar 

Brilli, L. et al. Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. Arch. Endocrinol. Metab. 64, 483–486 (2020).

PubMed  PubMed Central  Google Scholar 

Albarel, F. et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 172, 195–204 (2014).

Article  PubMed  Google Scholar 

Faje, A. T. et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99, 4078–4085 (2014).

Article  CAS  PubMed  Google Scholar 

Min, L. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749–755 (2015).

Article  CAS